Kala Bio Enters Exclusive U.S. Distribution Agreement for Virotek's Ophthalmology Genetic Tests
Kala Bio, Inc. (NASDAQ: KALA) has entered into an exclusive distribution and reseller agreement with Virotek Inc., granting it the sole rights to distribute Virotek’s ophthalmology genomic testing program in the United States starting September 4, 2026. The one-year deal includes marketing, promotion, and resale of genetic tests, contingent on Kala meeting commercial milestones for continued exclusivity. Virotek will manage infrastructure, supply kits, process specimens, and provide clinical reports while also offering training to Kala’s partners. A profit-sharing arrangement is set after Virotek recovers its costs. The partnership may expand into oncology, preventive health, telehealth, or white-label distribution if mutually agreed. Kala has not provided revenue forecasts for the agreement but cited market research estimating U.S. genetic testing at $5.7 billion in 2025 and projected to reach $6.9 billion by 2026.
Topics: distribution agreement genetic testing ophthalmology